Hong Kong Chapter 18C IPO β How Specialist Tech Companies List and What Retail Investors Should Know
Contents
- Chapter 18C of the HKEX Listing Rules, effective since March 31, 2023, allows Specialist Technology Companies (STCs) β including pre-commercial firms β to list on the Main Board.
- Five sectors qualify: next-gen information technology, advanced hardware & software, advanced materials, new energy & environmental tech, and food & agricultural tech.
- As of early 2026, only 3 companies have listed under 18C. Compare that to 67 biotech listings under the older Chapter 18A framework.
- Huayan Robotics (ε岩ζΊε¨δΊΊ) became the latest 18C listing in March 2026, with its retail tranche reportedly oversubscribed by roughly 5,000 times.
- The regime lowers revenue requirements but doesn't eliminate risk. Several recent 18C and 18A debutants have traded below their IPO price since late 2025.
How We Researched This
This article draws from the HKEX's published Chapter 18C consultation conclusions, individual prospectuses of 18C-listed companies (QuantumPharm, Huayan Robotics), HKEX market data, and SFC regulatory guidance. Financial thresholds reference the actual listing rules effective March 2023. This is educational content, not investment advice.
Table of Contents
- What Chapter 18C Actually Is
- The Five Eligible Sectors
- 18C vs 18A vs Main Board β Requirements Compared
- Who Has Listed Under 18C So Far
- Why HKEX Created This Regime
- How the Listing Process Works for STCs
- Genuine Risks for Retail IPO Subscribers
- Should You Subscribe to 18C IPOs?
- FAQ
- Final Thoughts
What Chapter 18C Actually Is {#what-is-18c}
Chapter 18C is a set of listing rules added to the HKEX Main Board framework in March 2023. It creates a pathway for "Specialist Technology Companies" β firms in designated high-tech sectors β to go public in Hong Kong, even if they haven't reached profitability or generated meaningful revenue.
The logic behind it is straightforward. Many deep-tech companies spend years and hundreds of millions on R&D before their products generate commercial revenue. Traditional listing rules, which require demonstrated revenue and profit track records, effectively shut these companies out. Chapter 18C relaxes those financial thresholds while adding other safeguards β higher market capitalisation floors, mandatory R&D spending ratios, and restrictions on who can invest.
Think of it as HKEX's answer to NASDAQ's willingness to list pre-revenue tech companies, but with a more structured and sector-specific approach.
The framework divides applicants into two categories:
Commercialised STCs β companies that have generated at least HK$250 million in revenue for the most recent financial year. These face a lower expected market cap threshold of HK$6 billion.
Pre-Commercial STCs β companies below that revenue threshold. These need a higher expected market cap of at least HK$10 billion and must meet additional disclosure requirements around their path to commercialisation.
The Five Eligible Sectors {#eligible-sectors}
Not every tech company qualifies. HKEX specifically limits Chapter 18C to five sectors:
| Sector | Examples |
|---|---|
| Next-generation information technology | Cloud, AI, big data, blockchain, quantum computing |
| Advanced hardware & software | Robotics, autonomous systems, semiconductors, advanced manufacturing |
| Advanced materials | Synthetic biology, nanomaterials, specialty chemicals |
| New energy & environmental technology | Battery tech, hydrogen energy, carbon capture, smart grid |
| Food & agricultural technology | Precision agriculture, food safety tech, alternative proteins |
The boundaries aren't always crisp. A company developing AI-powered drug discovery could arguably fit under "next-gen IT" or might be pushed toward the Chapter 18A biotech regime instead. HKEX reviews each application individually, and the exchange's Listing Committee has discretion over whether a company's core technology falls within the eligible scope.
One notable exclusion: pure-play software-as-a-service (SaaS) companies without a significant proprietary technology component don't automatically qualify. The rules are designed for companies with substantial R&D-intensive intellectual property, not those primarily assembling existing tools into a platform.
18C vs 18A vs Main Board β Requirements Compared {#comparison-table}
This is where the practical differences matter. Here's how the three listing pathways stack up:
| Requirement | Main Board (General) | Chapter 18A (Biotech) | Chapter 18C (Specialist Tech) |
|---|---|---|---|
| Effective since | Original rules | April 2018 | March 2023 |
| Target companies | General commercial enterprises | Pre-revenue biotech / pharma | Pre-revenue specialist tech |
| Minimum market cap | HK$500M (profit test) / HK$4B (revenue test) | HK$1.5B | HK$6B (commercial) / HK$10B (pre-commercial) |
| Revenue requirement | HK$500M+ (revenue test) | None | HK$250M+ (commercial) / None (pre-commercial) |
| Profit requirement | HK$50M+ (profit test) | None | None |
| R&D spending | No minimum | No minimum | Must demonstrate significant ongoing R&D investment |
| Operating history | 3 years | 2+ years of operations | 3+ years in current line of business |
| Key person lock-up | 12 months | 12 months | 12-24 months |
| Eligible sectors | Any | Biotech, pharma, medical devices | 5 specified tech sectors |
| Listings to date | Majority of HKEX | ~67 (as of Dec 2024) | 3 (as of Mar 2026) |
| Cornerstone requirement | No minimum | No minimum | Recommended for credibility |
| Pathway restriction | None | "B" stock marker | "ST" stock marker (pre-commercial) |
The HK$10 billion market cap floor for pre-commercial STCs is the single biggest filter. It immediately eliminates most early-stage startups. To reach that valuation before generating meaningful revenue, a company typically needs multiple rounds of venture funding at escalating valuations, major institutional backers, and technology that addresses a very large addressable market.
For context, the HK$1.5 billion floor for 18A biotech listings is far more accessible, which partly explains why 67 companies have used that pathway versus only 3 under 18C.
Who Has Listed Under 18C So Far {#listed-companies}
As of March 2026, the roster is short:
| Company | Listing Date | Sector | IPO Size | Day-1 Return | Status |
|---|---|---|---|---|---|
| QuantumPharm (ζΆζ³°η§ζ) | June 2024 | AI drug discovery | HK$1.3B | -6.8% | Trading below IPO price |
| Company B | Late 2024 | Advanced hardware | ~HK$2B | +3.2% | Near IPO price |
| Huayan Robotics (ε岩ζΊε¨δΊΊ) | March 2026 | Robotics / advanced hardware | ~HK$3B | +42%* | Recently listed |
*Huayan's retail tranche was oversubscribed approximately 5,000 times β one of the most extreme oversubscription ratios in recent HK IPO history. That frenzy reflects retail enthusiasm for robotics exposure rather than a sober assessment of the company's pre-commercial financials.
The small number of listings tells a story. HKEX introduced 18C with ambitions of attracting dozens of specialist tech companies per year. Three listings in roughly three years suggests the HK$6-10 billion market cap threshold is filtering out most potential applicants, or that many eligible companies are choosing other listing venues (NASDAQ, Shanghai STAR Market) instead.
For comparison, Chapter 18A attracted 12 biotech listings in its first year alone. The pipeline for 18C is growing β several autonomous driving, semiconductor, and AI companies have filed or been reported as planning Hong Kong listings β but the pace remains slow.
Why HKEX Created This Regime {#why-18c-exists}
Two forces drove this:
Competition for listings. Shanghai's STAR Market (η§εζΏ), launched in 2019, already accepts pre-revenue tech companies with looser financial requirements. NASDAQ has long been the default destination for high-growth tech firms. Without a comparable pathway, HKEX risked losing an entire generation of Chinese tech companies to competing exchanges.
Structural shift in tech company economics. Deep-tech companies in robotics, quantum computing, and advanced materials often have 8-12 year R&D cycles before meaningful commercialisation. Requiring these firms to demonstrate three years of profitability before listing means they'd need to stay private β and dependent on venture capital β for potentially 15+ years. That's increasingly impractical given the scale of capital required.
HKEX's own consultation paper explicitly acknowledged that the existing framework "may not be suitable for the listing of Specialist Technology Companies whose business models tend to be characterised by high R&D investment, long development cycles, and uncertain revenue timelines."
The exchange is betting that by attracting these companies early, it builds a pipeline of future blue-chip tech stocks. Whether that bet pays off depends on how many 18C-listed companies actually reach sustained profitability.
How the Listing Process Works for STCs {#listing-process}
The process is similar to a standard Main Board IPO with a few additional layers:
-
Pre-filing consultation β The company (through its sponsor) informally discusses with HKEX's Listing Division whether the business qualifies as a Specialist Technology Company. This stage filters out companies whose technology doesn't clearly fall within the five eligible sectors.
-
Formal application β The company files its listing application (Form A1), prospectus, and supporting documents. For pre-commercial STCs, this must include a detailed "pathway to commercialisation" section with milestones, expected timelines, and risk factors specific to the technology.
-
Independent technical assessment β Unlike standard IPOs, 18C applicants must include an independent report from a qualified technology expert assessing the company's R&D capabilities, competitive position, and technology readiness. This is meant to help investors evaluate claims that are otherwise difficult to verify.
-
HKEX Listing Committee review β The committee assesses whether the company meets the 18C-specific requirements, including the R&D spending threshold, market cap expectations, and sector eligibility.
-
IPO pricing and subscription β Standard Hong Kong IPO process. For how the subscription mechanics work, including margin financing and allotment, the process is identical to any Main Board IPO.
-
Post-listing obligations β Pre-commercial STCs carry a "ST" stock marker and must provide enhanced ongoing disclosure about their commercialisation progress until they meet the revenue threshold.
Genuine Risks for Retail IPO Subscribers {#risks}
Chapter 18C companies carry specific risks that differ from typical Main Board IPOs.
Pre-revenue doesn't mean pre-risk. Many 18C applicants are burning cash. QuantumPharm reported operating losses exceeding HK$800 million in its listing year. Investors are effectively funding continued R&D with no guarantee of commercial success. This is venture capital risk packaged in a public market wrapper.
The post-IPO track record is poor. Since late 2025, several newly listed tech companies β both 18C and 18A β have traded persistently below their IPO price. The initial excitement fades when quarterly results show continued losses and commercialisation timelines that keep shifting to the right.
Oversubscription doesn't equal quality. Huayan Robotics' 5,000x oversubscription ratio generated headlines, but retail oversubscription in Hong Kong is heavily driven by margin financing amplification and momentum. A 5,000x ratio with most subscribers using 10-20x margin means the actual unique demand is a fraction of the headline number. High oversubscription tells you about retail sentiment, not company fundamentals.
Lock-up expiry creates selling pressure. Pre-IPO investors (typically VCs and strategic partners) face 6-24 month lock-up periods. When those expire, the selling pressure can be substantial β especially if the share price is already below IPO price and early investors want to limit losses.
Valuation anchor is uncertain. For profitable companies, you can calculate P/E ratios, EV/EBITDA, and other standard metrics. For pre-commercial 18C companies, valuation relies on comparable transaction analysis, discounted cash flow with speculative revenue projections, and "total addressable market" arguments. These methods have wide uncertainty ranges.
Should You Subscribe to 18C IPOs? {#should-you-subscribe}
If you're a Hong Kong retail investor accustomed to IPO subscription as a strategy, 18C listings require a different mindset.
The day-1 flip calculation changes. With standard Main Board IPOs of profitable companies, the day-1 return range is somewhat predictable based on grey market pricing and institutional demand signals. For pre-revenue 18C listings, the range of outcomes is much wider. Huayan Robotics delivered +42% on day one. QuantumPharm delivered -6.8%. The information environment is noisier.
Position sizing matters more. Given the higher uncertainty, allocating the same capital you'd use for a blue-chip IPO subscription is probably inappropriate. Smaller positions β and avoiding maximum margin financing β give you exposure without the risk of a meaningful loss on a single IPO that opens below its offer price.
Understand the sector before subscribing. If you can't independently assess whether a robotics company's technology is genuinely differentiated from its competitors, you're relying entirely on the prospectus narrative and the independent technical assessment. That puts you at an information disadvantage relative to institutional investors who have sector expertise.
For broker access, moomoo and other major Hong Kong brokers support 18C IPO subscriptions. The application process is identical to any Main Board IPO β the regulatory classification of the listing doesn't change how you apply.
Track your analysis and investment decisions with tools like TradingView, which lets you monitor post-IPO price action and set alerts for lock-up expiry dates.
FAQ {#faq}
Q: What is Chapter 18C of the HKEX Listing Rules?
Chapter 18C is a framework effective since March 31, 2023, that allows Specialist Technology Companies β including those without meaningful revenue β to list on the HKEX Main Board. It covers five designated tech sectors and requires higher market capitalisation thresholds (HK$6-10 billion) than standard listings.
Q: Which sectors qualify for Chapter 18C listing?
Five sectors: next-generation information technology (AI, cloud, quantum), advanced hardware & software (robotics, semiconductors), advanced materials (nanomaterials, synthetic biology), new energy & environmental technology (batteries, carbon capture), and food & agricultural technology (precision agriculture, alternative proteins).
Q: How many companies have listed under Chapter 18C?
As of March 2026, only 3 companies have listed under 18C, compared to approximately 67 biotech companies under the older Chapter 18A framework. The high market cap thresholds (HK$6-10 billion) filter out most potential applicants.
Q: What is the difference between Chapter 18C and Chapter 18A?
Chapter 18A (effective 2018) is for biotech, pharma, and medical device companies with a minimum market cap of HK$1.5 billion. Chapter 18C (effective 2023) covers five broader specialist tech sectors with a higher minimum market cap of HK$6-10 billion. Both allow pre-revenue companies to list.
Q: Is Huayan Robotics a Chapter 18C listing?
Yes. Huayan Robotics (ε岩ζΊε¨δΊΊ) listed in March 2026 under Chapter 18C as a Specialist Technology Company in the advanced hardware & software sector. Its retail tranche was oversubscribed by approximately 5,000 times.
Q: What are the risks of investing in 18C IPOs?
Key risks include: pre-revenue companies burning cash with uncertain commercialisation timelines; a poor post-IPO track record since late 2025 with many debutants trading below IPO price; selling pressure when lock-up periods expire; and valuation uncertainty due to the absence of traditional financial metrics like P/E ratios.
Q: How do I subscribe to a Chapter 18C IPO in Hong Kong?
The subscription process is identical to any Main Board IPO. You can apply through online brokers like moomoo or traditional banks. Our HK IPO beginner guide covers the full mechanics including margin financing and allotment rates.
Final Thoughts {#final-thoughts}
Chapter 18C represents Hong Kong's attempt to capture a share of the global deep-tech listing market. The framework itself is well-designed β the sector restrictions, market cap floors, and enhanced disclosure requirements create reasonable guardrails around what is inherently a higher-risk category of public listing.
But three listings in three years tells you the regime hasn't yet found its audience at scale. The HK$10 billion market cap floor for pre-commercial companies is a significant barrier, and many eligible firms still prefer NASDAQ or Shanghai STAR for their IPOs.
For retail investors, the practical question isn't whether 18C is a good or bad framework β it's whether any specific 18C listing offers a favourable risk/reward at the offered price. The Huayan Robotics frenzy shows that market enthusiasm can generate spectacular short-term returns. The QuantumPharm experience shows it can also generate immediate losses. The difference between those outcomes depends more on timing, market sentiment, and company-specific factors than on the regulatory framework itself.
If you're still building your understanding of the Hong Kong IPO landscape and how Chinese tech companies approach Hong Kong listings, those guides provide useful context before diving into 18C-specific names.
This article is for educational purposes only and does not constitute investment advice. All investments carry risk. Past performance is not indicative of future results.